A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV
Conditions
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease · HIV (Human Immunodeficiency Virus)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama Birmingham, Birmingham, Alabama, United States
Contact: Principal Investigator (Sonya Heath, MD)UC San Diego Altman Clinical and Translational Research Institute, La Jolla, California, United States
Contact: Principal Investigator (Rohit Loomba, MD)University of California, San Francisco, San Francisco, California, United States
Contact: Principal Investigator (Jennifer Price, MD)Atlantic Clinical Research Institute, West Palm Beach, Florida, United States
Contact: Principal Investigator (Hector Bolivar, MD)Indiana University, Indianapolis, Indiana, United States
Contact: Principal Investigator (Samer Gawrieh, MD)Johns Hopkins University, Baltimore, Maryland, United States
Contact: Principal Investigator (Mark Sulkowski, MD)Mt Sinai Health System, New York, New York, United States
Contact: Principal Investigator (Meena Bansal, MD)Duke University Medical Center, Durham, North Carolina, United States
Contact: Principal Investigator (Susanna Naggie, MD)UT Health Houston, Houston, Texas, United States
Contact: Principal Investigator (Jordan Lake, MD)Virginia Commonwealth University, Richmond, Virginia, United States
Contact: Study coordinator (Dianne Boyce Grogan) · dianne.boycegrogan@vcuhealth.org · 1-804-828-2988Contact: Principal Investigator (Richard Sterling, MD)